Rocket Pharmaceuticals received FDA approval for Kresladi, a gene therapy for leukocyte-adhesion deficiency type 1 (LAD-1), according to reporting from MedCity News. The approval is framed as the first commercial gene therapy for this ultra-rare immune disorder, and the first for Rocket. The approval expands Rocket’s role in inherited immune disease gene therapy and demonstrates continued regulatory pathways for ultra-rare indications where clinical development can be accelerated by biological severity. For the platform, each new indication provides incremental data on manufacturing consistency, durability of expression, and safety monitoring in routine practice. The approval also adds to the competitive landscape of gene therapy developers targeting rare immunodeficiencies, where reimbursement, long-term outcomes, and real-world monitoring remain critical decision points for payers and health systems.